Oramed Pharmaceuticals to Present at the IATI Israel Innovation Conference in Tel Aviv Oramed to Present on Tuesday, May 20, 2014, at 4:10 p.m. (IDT)
JERUSALEM, May 19, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a clinical-stage developer of oral delivery systems, announced today that Josh Hexter, Oramed's Chief Operating Officer and Vice President of Business Development, will present a corporate overview at the IATI Israel Innovation Conference/MIXiii taking place May 20-22, 2014, in Tel Aviv, Israel.
Conference and Presentation Details
IATI Biomed 2014 - Israel Innovation Conference MIXiii
Date: Tuesday, May 20, 2014
Time: 9:10am EDT/4:10pm local time
Location: Tel-Aviv Fairgrounds
The IATI Israel Innovation Conference follows the success of previous annual conferences that hosted over 7,000 industry players, engineers and scientists with approximately 1,500 participants from over 45 countries and an excess of 4,500 one-on-one meetings.
About the IATI Israel Innovation Conference (MIXiii)
The Israel Innovation Conference, formerly known as the IATI-BioMed Conference, will be the first in the world where Biomed and High-tech will join hands in a unique and exciting new international conference format. The IATI-BioMed conference has been Israel's premier life science conference showcasing the country's most advanced companies and technologies, now to incorporate High-tech into the mix of its successful format. Building on the great reputation established in previous years, MIXiii offers attendees and presenters a winning mix of industry keynote speakers, exciting and innovative company presentations, and three days of exhibition and networking opportunities.
For more information on the Israel Innovation Conference, the content of which is not part of this press release, please visit: http://mixiii.com/
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in separate Phase II clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering IND-enabling studies later this year.
For more information, the content of which is not part of this press release, please visit: http://www.oramed.com
Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected design or timing thereof, the anticipated safety of ORMD-0801 and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
US Investor Relations Contact:
LifeSci Advisors LLC
SOURCE Oramed Pharmaceuticals Inc.